What are the latest recommendations for frontline acute lymphoblastic leukemia (ALL) treatment? In this episode of CancerSpeak, Cancer Hematologic Malignancies Section Editor Dr. Courtney DiNardo is joined by Dr. Daniel DeAngelo and Dr. David McCall to discuss a new international expert consensus statement on optimizing the safety and efficacy of asparaginase and blinatumomab in frontline ALL treatment. They walk through the key recommendations from the consensus statement, exploring how these therapies fit into modern treatment approaches and what clinicians should consider when applying these strategies across different healthcare settings.
Read the full consensus statement in Cancer: <a href='https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70559'>https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70559</a>
Follow Cancer on social media: 
<a href='https://x.com/JournalCancer'>x.com/JournalCancer</a> 
<a href='https://www.instagram.com/acsjournals'>instagram.com/acsjournals</a> 
<a href='http://linkedin.com/company/acs-journals'>linkedin.com/company/acs-journals</a>
Original music by J. Gilman.

What are the latest recommendations for frontline acute lymphoblastic leukemia (ALL) treatment? In this episode of CancerSpeak, Cancer Hematologic Malignancies Section Editor Dr. Courtney DiNardo is joined by Dr. Daniel DeAngelo and Dr. David McCall to discuss a new international expert consensus statement on optimizing the safety and efficacy of asparaginase and blinatumomab in frontline ALL treatment. They walk through the key recommendations from the consensus statement, exploring how these therapies fit into modern treatment approaches and what clinicians should consider when applying these strategies across different healthcare settings.
Read the full consensus statement in Cancer: <a href='https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70559'>https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70559</a>
Follow Cancer on social media:
<a href='https://x.com/JournalCancer'>x.com/JournalCancer</a>
<a href='https://www.instagram.com/acsjournals'>instagram.com/acsjournals</a>
<a href='http://linkedin.com/company/acs-journals'>linkedin.com/company/acs-journals</a>
Original music by J. Gilman.

What are the latest recommendations for frontline acute lymphoblastic leukemia (ALL) treatment? In this episode of CancerSpeak, Cancer Hematologic Malignancies Section Editor Dr. Courtney DiNardo is joined by Dr. Daniel DeAngelo and Dr. David McCall to discuss a new international expert consensus statement on optimizing the safety and efficacy of asparaginase and blinatumomab in frontline ALL treatment. They walk through the key recommendations from the consensus statement, exploring how these therapies fit into modern treatment approaches and what clinicians should consider when applying these strategies across different healthcare settings.
Read the full consensus statement in Cancer: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.70559
Follow Cancer on social media:x.com/JournalCancerinstagram.com/acsjournalslinkedin.com/company/acs-journals
Original music by J. Gilman.

Optimizing Asparaginase and Blinatumomab in Frontline Acute Lymphoblastic Leukemia

Description